JPMorgan Chase & Co. Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE) had its price objective raised by JPMorgan Chase & Co. from $62.00 to $86.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a neutral rating on the medical instruments supplier’s stock.

HAE has been the topic of several other research reports. Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. Bank of America raised Haemonetics from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. BTIG Research boosted their target price on Haemonetics from $84.00 to $96.00 and gave the company a “buy” rating in a report on Thursday. Finally, Barrington Research set a $95.00 price target on Haemonetics in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.89.

Haemonetics Trading Up 2.9%

Shares of Haemonetics stock opened at $87.50 on Friday. Haemonetics has a 1 year low of $47.31 and a 1 year high of $88.58. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.87 and a current ratio of 3.08. The company has a market capitalization of $3.98 billion, a P/E ratio of 42.89, a PEG ratio of 1.71 and a beta of 0.52. The company’s fifty day moving average is $76.98 and its two-hundred day moving average is $66.52.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business had revenue of $339.38 million during the quarter, compared to analysts’ expectations of $327.86 million. During the same period in the prior year, the company earned $1.10 earnings per share. The business’s revenue was up 5.5% compared to the same quarter last year. Analysts forecast that Haemonetics will post 5.21 earnings per share for the current year.

Hedge Funds Weigh In On Haemonetics

A number of large investors have recently made changes to their positions in HAE. Kemnay Advisory Services Inc. acquired a new position in Haemonetics during the fourth quarter worth about $26,000. Leonteq Securities AG acquired a new stake in shares of Haemonetics during the 4th quarter valued at approximately $30,000. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Haemonetics during the 4th quarter valued at approximately $34,000. Finally, Bayforest Capital Ltd purchased a new stake in shares of Haemonetics during the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.